Treatments and Therapies | Alzheimer's Society

What is lecanemab?

Lecanemab made headlines as the first MHRA-approved drug in the UK to slow early-stage Alzheimer’s disease, but it has not been recommended for NHS at this stage. Here is what we know so far about this breakthrough Alzheimer's drug.

Research

Intepirdine fails to treat Alzheimer’s disease in Phase 3 trial

Axovant Sciences today announced that the Phase 3 MINDSET trial of its Alzheimer’s drug intepirdine has failed to bring meaningful improvements in cognition or daily functioning.

Lithium in drinking water could protect against dementia, study finds – Alzheimer’s Society comments

People exposed to higher levels of lithium in their drinking water are at a reduced risk of dementia, according to a large study published today (Wednesday 23 August 2017) in JAMA Psychiatry.

Alzheimer’s Society ‘Centres of Excellence’ could make a life-changing difference for people affected by dementia

Alzheimer’s Society has today announced its biggest-ever single investment in dementia care research. £6 million has been awarded to three ‘Centres of Excellence'.

What is lecanemab?

Intepirdine fails to treat Alzheimer’s disease in Phase 3 trial

Lithium in drinking water could protect against dementia, study finds – Alzheimer’s Society comments

Alzheimer’s Society ‘Centres of Excellence’ could make a life-changing difference for people affected by dementia

Useful links